表决结果：9票同意、0票反对、0票弃权。 证券代码：002252 证券简称：上海莱士 公告编号：2023-063 上海莱士血液制品股份有限公司 关于第五届董事会第二十七次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第五届董事会第二十七次会议于 2023 年 8 月 18 日以电话和邮件方式发出会议通知，并于 2023 年 8 月 28 日下午 3 点以通讯方式召开。 本次会议应出席董事 9 名，实际出席董事 9 名。本次会议由公司董事长、总 经理 Jun Xu（徐俊）先生召集和主持。会议的召集召开与表决程序符合《公司 法》和《公司章程》等的有关规定。会议在保证所有董事充分发表意见的前提下， 全体与会董事经投票表决，一致作出如下决议： 1、审议通过了《2023 年半年度报告全文及摘要》 《2023年半年度报告》全文刊登于巨潮资讯网（www.cninfo.com.cn），《2023 年半年度报告摘要》同时刊登于《证券时报》、《中国证券报》、《上海证券报》、 《证券日报》和巨潮资讯网（www.cninfo. ...

一、报告期内关联交易及关联方资金占用情况 根据《上市公司监管指引第8号——上市公司资金往来、对外担保的监管要 求》、《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运 作》、《上市公司独立董事规则》等规定和要求，同时根据《公司章程》、《董事 会议事规则》、《独立董事工作制度》等有关规定赋予独立董事的职责，我们作为 上海莱士血液制品股份有限公司（"公司"）独立董事，本着勤勉尽责的态度， 基于独立判断，对本报告期（2023年1月1日至2023年6月30日）公司关联方资金 往来及对外担保情况进行了认真核查，现将有关情况说明如下： 上海莱士血液制品股份有限公司 1、报告期内，公司不存在控股股东及其他关联方因非经营性事项形成对公 司资金占用的情形；也不存在以前期间发生并延续到报告期的控股股东及其他关 联方非经营性占用公司资金的情况。 独立董事关于关联方占用公司资金、公司对外担保情况的 专项说明和独立意见 2、经核查，报告期内公司发生的关联交易主要如下： （3）2022年4月，公司与关联方Grifols Diagnostic Solutions Inc.,（"GDS"） 签署了《独家经销协议》（"协议"）， ...

上海莱士血液制品股份有限公司监事会 关于2023年半年度报告的书面审核意见 上海莱士血液制品股份有限公司（"公司"）第五届监事会第二十次会议对《上 海莱士血液制品股份有限公司2023年半年度报告全文及摘要》进行认真审核。经 审核，监事会认为： 董事会编制和审核公司2023年半年度报告全文及摘要的程序符合法律、行政 法规和中国证券监督管理委员会的相关规定，报告内容真实、准确、完整地反映 了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 （以下无正文） （以下无正文，为《上海莱士血液制品股份有限公司监事会关于 2023 年半年度 报告的书面审核意见》签字页） 监事签字： 上海莱士血液制品股份有限公司 监事会 二〇二三年八月二十八日 ...

上海莱士血液制品股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"上海莱士"或"公司"）于 2023 年 8 月 28 日召开了第五届董事会第二十七次会议及第五届监事会第二十次会议，审议 通过了《2023 年半年度募集资金存放与使用情况的专项报告》等，根据中国证 券监督管理委员会（"中国证监会"）发布的《上市公司监管指引第 2 号——上市 公司募集资金管理和使用的监管要求》（证监会公告〔2022〕15 号）和深圳证券 交易所（"深交所"）颁布的《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》、《深圳证券交易所上市公司自律监管指南第 2 号——公 告格式》中关于上市公司募集资金年度存放与使用情况公告格式等有关规定，董 事会编制了截至 2023 年 6 月 30 日募集资金存放与使用情况的专项报告，具体公 告如下： 一、募集资金基本情况 （一）实际募集资金金额及资金到账时间 2014 年 12 月 17 日，经中国证监会"证监许可［2014］1 ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-064 上海莱士血液制品股份有限公司 关于第五届监事会第二十次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）第五届监事会第二十次会议于 2023 年 8 月 18 日以电子邮件和电话方式发出通知，并于 2023 年 8 月 28 日下午 4 点以通讯方式召开。 会议应出席监事 3 名，实际出席监事 3 名。本次会议由监事会主席胡维兵先 生召集和主持。会议的召集召开与表决程序符合《公司法》和《公司章程》的有 关规定。会议在保证所有监事充分发表意见的前提下，全体与会监事经投票表决， 一致作出如下决议： 《2023 年半年度募集资金存放与使用情况的专项报告》全文刊登于《证券 时 报 》、《 中 国 证 券 报 》、《 上 海 证 券 报 》、《 证 券 日 报 》 和 巨 潮 资 讯 网 （www.cninfo.com.cn），供投资者查阅。 特此公告。 上海莱士血液制品股份有限公司 监事会 二〇二三年八月三十日 经审核，监事会认为：董事会编制和 ...

北京国枫律师事务所 关于上海莱士血液制品股份有限公司 2023 年第二次临时股东大会的法律意见书 国枫律股字[2023]A0438 号 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编：100005 电话（Tel）：010-88004488/66090088 传真（Fax）：010-66090016 北京国枫律师事务所 关于上海莱士血液制品股份有限公司 2023 年第二次临时股东大会的法律意见书 国枫律股字[2023]A0438 号 致：上海莱士血液制品股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2023 年第二次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以 下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试 行）》（以下简称"《证券 ...

证券简称：上海莱士 证券代码：002252 上海莱士血液制品股份有限公司 第一期员工持股计划 （本计划主要条款与公司2023年8月1日公告的员工持股计划草案及其摘要内容一致） $$\Xi{\bf{\hat{O}}}\,{\bf{\hat{=}}}\,\Xi{\bf{\hat{\mp}}}\,J(\backslash\,\Xi)$$ 上海莱士血液制品股份有限公司第一期员工持股计划 声明 本公司及董事会全体成员保证本员工持股计划的内容真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏。 2 上海莱士血液制品股份有限公司第一期员工持股计划 风险提示 一、本员工持股计划已经公司股东大会批准。 二、有关本员工持股计划的资金来源、出资比例、实施方案等属初步结果， 本员工持股计划能否完成实施，存在不确定性。 三、员工遵循依法合规、自愿参与、风险自担的原则参与本员工持股计划。 若员工认购金额较低时，则本员工持股计划存在不能成立的风险；若员工认购资 金不足，则本员工持股计划存在低于预计规模的风险。 四、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 3 上海莱士血液制品股份有限公司第一期员工 ...

证券代码：002252 证券简称：上海莱士 公告编号：2023-061 上海莱士血液制品股份有限公司 2023 年第二次临时股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更、否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间为：2023 年 8 月 16 日（星期三）14:00； 网络投票时间为：2023 年 8 月 16 日（星期三）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2023 年 8 月 16 日的交易时间，即 9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2023 年 8 月 16 日 9:15 至 15:00 期间的任意时 间。 2、现场会议召开地点：上海市奉贤区环城东路 473 号上海南桥绿地铂骊酒店。 1、股东出席的总体情况 通过现场和网络投票方式出席会议的股东及股东授权委托代表 367 人，代表股份 ...

Financial Performance - The company's revenue for Q1 2023 was ¥2,063,038,679.08, representing a 22.40% increase compared to ¥1,685,498,423.72 in the same period last year[3] - Net profit attributable to shareholders was ¥718,568,079.44, up 31.12% from ¥548,033,363.89 year-on-year[3] - Basic earnings per share rose to ¥0.107, reflecting a 32.10% increase from ¥0.081 in the same quarter last year[3] - Total operating revenue for the current period reached ¥2,063,038,679.08, a 22.4% increase from ¥1,685,498,423.72 in the previous period[16] - Net profit for the current period was ¥718,266,042.76, representing a 31.4% increase compared to ¥545,987,550.05 in the previous period[17] - Operating profit rose to ¥842,272,279.67, an increase of 30.5% from ¥645,693,141.36 in the previous period[17] - The company reported a total comprehensive income of ¥528,071,210.89, compared to ¥479,205,487.47 in the previous period[17] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥1,070,515,512.59, a significant increase of 157.77% compared to ¥415,302,906.87 in the previous year[3] - Cash flow from operating activities generated a net amount of ¥1,070,515,512.59, significantly up from ¥415,302,906.87 in the previous period[20] - Cash and cash equivalents at the end of the period totaled ¥3,631,414,859.74, compared to ¥2,660,030,335.64 at the end of the previous period[21] - The company's cash and cash equivalents increased to RMB 4,569,595,868.99 from RMB 3,977,425,328.72, representing a growth of about 14.8%[11] - The company reported a significant increase in cash reserves, which may support future investments and operational expansions[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥31,008,256,414.76, a 1.81% increase from ¥30,457,959,495.12 at the end of the previous year[3] - The total liabilities of the company as of March 31, 2023, were RMB 1,666,806,771.14, slightly up from RMB 1,644,618,113.59 at the beginning of the year[13] - The equity attributable to shareholders of the parent company increased to RMB 29,347,122,761.37 from RMB 28,818,712,462.60, reflecting a growth of approximately 1.8%[13] - The company's non-current assets totaled RMB 22,354,391,292.06, up from RMB 21,984,549,673.90, indicating an increase of about 1.7%[12] Research and Development - The company's R&D expenses increased by 33.77% to ¥46,017,682.81, driven by an expansion in research activities[6] - Research and development expenses increased to ¥46,017,682.81, up from ¥34,400,140.41 in the previous period, indicating a focus on innovation[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 123,870, with the largest shareholder holding 26.20% of the shares[8] Other Financial Metrics - The weighted average return on equity improved to 2.47%, up 0.37 percentage points from 2.10% in the previous year[3] - The company experienced a 99.61% decrease in other current assets, primarily due to a reduction in deductible VAT input tax[6] - Accounts receivable decreased to RMB 523,036,139.16 from RMB 707,021,384.74, indicating a decline of approximately 26%[11] - Inventory levels decreased to RMB 3,064,179,372.22 from RMB 3,268,843,130.57, showing a reduction of about 6.3%[12] - The company reported a significant increase in government subsidies, totaling ¥2,427,675.03, although this was a 39.82% decrease compared to the previous year[7] - The company's short-term borrowings and other financial liabilities were not detailed in the provided data, indicating a focus on operational liquidity management[13] - The overall financial health of the company appears stable, with a solid increase in total assets and equity, despite some declines in receivables and inventory levels[14]

Financial Performance - The company's operating revenue for 2022 was ¥6,567,198,581.04, representing a 53.16% increase compared to ¥4,287,726,749.67 in 2021[11]. - The net profit attributable to shareholders for 2022 was ¥1,880,090,066.90, up 45.24% from ¥1,294,510,050.46 in 2021[11]. - The net profit after deducting non-recurring gains and losses was ¥1,826,062,740.20, a 33.40% increase from ¥1,368,820,159.04 in 2021[11]. - The net cash flow from operating activities for 2022 was ¥1,725,596,063.70, reflecting a 33.35% increase compared to ¥1,294,013,219.19 in 2021[11]. - The total assets at the end of 2022 were ¥30,457,959,495.12, an 11.83% increase from ¥27,236,582,048.82 at the end of 2021[11]. - The net assets attributable to shareholders at the end of 2022 were ¥28,818,712,462.60, up 11.26% from ¥25,902,445,517.58 at the end of 2021[11]. - The company reported a weighted average return on equity of 6.87% for 2022, an increase of 1.79 percentage points from 5.08% in 2021[11]. - The company's total revenue for 2022 reached ¥6,567,198,581.04, representing a 53.16% increase compared to ¥4,287,726,749.67 in 2021[41]. - The blood product segment generated ¥6,504,836,891.84, accounting for 99.05% of total revenue, with a year-on-year growth of 51.81%[41]. - The company reported a total operating cost of approximately CNY 3.67 billion, a 77.56% increase from the previous year[45]. Dividend Distribution - The company plans to distribute a cash dividend of 0.30 RMB per 10 shares to all shareholders, with no bonus shares or capital increase from reserves[2]. - The total cash dividend for the year 2022 was RMB 202,223,637.21, which is inclusive of all distribution methods[139]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution[139]. - The company’s cash dividend policy complies with relevant laws and regulations, ensuring protection for minority shareholders[138]. Market Position and Growth - The blood product industry is experiencing steady growth due to increased clinical application and market demand, despite external pressures[15]. - The company is a leading player in China's blood products industry, with a comprehensive product range and high plasma utilization rate[22]. - The company has seen a notable increase in market share through collaboration with key opinion leaders in various medical fields, enhancing its brand image and industry leadership[24]. - The company is positioned to benefit from the increasing concentration in the blood products industry, with major players dominating the market[21]. - The company has achieved a record plasma collection volume of over 1,400 tons during the reporting period, marking a historical high[33]. - The company operates 42 plasma collection stations across 11 provinces, ranking among the top in the industry for both station count and plasma collection volume[23]. Research and Development - The company is actively pursuing research and development in hemophilia treatment and exploring new clinical indications for its products[34]. - The company is in the pre-clinical development stage for several new products, including a 10% intravenous immunoglobulin and an activated prothrombin complex, aimed at enhancing product lines and competitiveness[54]. - The company plans to continue its commitment to research and development to drive innovation in blood product solutions[100]. - The company is investing CNY 500 million in R&D for new blood product technologies over the next three years[148]. Operational Efficiency and Management - The company has strengthened its management and operational strategies to enhance plasma source expansion, focusing on both existing and new plasma collection stations[32]. - The company has implemented a comprehensive quality management system, ensuring the safety, quality, and efficiency of its products[35]. - The company has enhanced its internal management efficiency and operational levels, focusing on a high-standard quality management system[38]. - The company aims to optimize resource allocation and improve cost control in its plasma station operations[83]. - The company is focused on expanding its plasma source and improving operational management capabilities[83]. Risks and Challenges - The company faces risks including raw material supply, rising plasma costs, potential product safety issues, and goodwill impairment[2]. - The supply-demand imbalance for raw plasma remains significant, with the number of single plasma collection stations in China being insufficient to meet actual demand[16]. - The company is exposed to currency exchange risks due to its import trade primarily settled in USD and plans to monitor foreign currency transactions to mitigate this risk[91]. Corporate Governance - The company has established a complete and clear internal governance structure, complying with relevant laws and regulations[93]. - The company is committed to enhancing its corporate governance structure by filling independent director positions as required by regulations[101]. - The company continues to strengthen its internal control system to improve governance levels[93]. - The company has made revisions to its governance documents, including the company charter and shareholder meeting rules, to improve operational efficiency[126]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[146]. - The company has implemented measures to ensure compliance with environmental standards and regulations[146]. - The wastewater treatment facility operates with a process including regulation, acid hydrolysis, and disinfection, ensuring effective pollutant removal[163]. - The company has received multiple environmental approvals for its projects, including a recent wastewater discharge permit valid until December 2023[159]. Strategic Partnerships and Acquisitions - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product portfolio[100]. - The company has completed two strategic acquisitions in 2022, enhancing its production capacity by 30%[150]. - The company has established exclusive distribution rights for Grifols, S.A. products in China, excluding Hong Kong, Macau, and Taiwan[192]. Employee Management and Welfare - The total number of employees at the end of the reporting period was 3,121, with 618 in the parent company and 2,503 in major subsidiaries[131]. - The company provided additional benefits such as paid leave, annual health checks, and supplementary medical insurance to enhance employee welfare[133]. - The company implemented a performance-based salary adjustment and bonus distribution policy to align organizational goals with individual objectives[133].